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The rise of antibiotic-resistance as well as the reduction of investments by pharmaceutical companies in the
development of new antibiotics have stimulated the investigation for alternative strategies to conventional
antibiotics. Many antimicrobial peptides show a high specificity for prokaryotes and a low toxicity for eukaryotic cells
and, due to their mode of action the development of resistance is considered unlikely. We recently characterized an
antimicrobial peptide that was called Paracentrin 1 from the 5-kDa peptide fraction from the coelomocyte cytosol of
the Paracentrotus lividus. In this study, the chemically synthesized Paracentrin 1, was tested for its antimicrobial and
antibiofilm properties against reference strains of Gram positive and Gram negative. The Paracentrin 1 was active
against planktonic form of staphylococcal strains (reference and isolates) and Pseudomonas aeruginosa ATCC 15442
at concentrations ranging from 12.5 to 6.2 mg/ml. The Paracentrin 1 was able to inhibit biofilm formation of
staphylococcal and Pseudomonas aeruginosa strains at concentrations ranging from 3.1 to 0.75 mg/ml. We consider the
tested peptide as a good starting molecule for novel synthetic derivatives with improved pharmaceutical potential.
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Many natural antimicrobial peptides show a high specificity
for prokaryotes and a low toxicity for eukaryotic cells, and
for their mode of action the development of resistance by
pathogenic bacteria is considered unlikely (Hancock and
Rozek 2002). At present, there has been an increase of
interest in these molecules as potential new antimicrobials
(Bax et al. 2000; Mor 2000).
In human medicine, chronic and persistent forms of
some infectious diseases depend on the ability of
pathogenic bacteria to develop bacterial communities called
biofilms. Opportunistic pathogens, such as staphylococcal
strains and Pseudomonas aeruginosa show a great ability to
produce biofilms that preventing infected wounds to heal,
render the treatment extremely challenging. In veterinary* Correspondence: domenico.schillaci@unipa.it
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in any medium, provided the original work is pmedicine, biofilms are believed to be involved in many
diseases such as pneumonia, liver abscesses, enteritis,
wound infections and mastitis, which is one of the most
common diseases in dairy cattle (Clutterbuck et al. 2007).
Staphylococcus aureus, a major pathogen of mastitis has
good in vitro antimicrobial susceptibility, but the therapy
used to treat the affected animals is often disappointing and
results in chronic infections due to the growth of bacteria
as biofilms (Melchior et al. 2006). The biofilm of P.
aeruginosa is a severe complicating factor in bovine
mastitis, which is often associated with contaminated udder
washing water or contaminated intramammary dry-cow
preparations (Melchior et al. 2009).
The treatment of biofilm-associated infections is
complicated because microbial biofilms are typically highly
resistant to conventional antibiotics (Gilbert et al. 2002).
The discovery of anti-infective agents active not only
against planktonic microorganisms but also against biofilmsan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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infections (Projan and Youngman 2002).
The antimicrobial defence system of marine invertebrates
is an interesting source of new anti-infective agents (Arizza
2013). We focused, particularly, on the effector cells of the
echinoderm immune system, the coelomocytes. In a recent
study, the antimicrobial activity of a 5-kDa peptide fraction
from coelomocyte cytosol (5-CC) of the Paracentrotus
lividus, the sea-urchin from Mediterranean sea, was
demonstrated in relation to a group of important human
pathogens. The anti-biofilm activity of 5-CC was shown in
S. epidermidis 1457, a clinical strain isolated from an
infected central venous catheter, against reference staphylo-
coccal biofilms and against Candida albicans and Candida
tropicalis (Schillaci et al. 2010; Schillaci et al. 2012). We
showed the presence of three principal peptides, in the
5-CC content, whose molecular weights were respectively
1251.7, 2088.1, and 2292.2. These peptides are the (9–19),
(12–31), (24–41) fragments of a β-thymosin of P. lividus.
We focused particularly on the smallest peptide, that we
called paracentrin 1, 11 amino acids in length, because
showed the common chemical-physical characteristics of
an antimicrobial peptide (Wang and Wang 2004).
The present study was aimed at evaluating the antibac-
terial and anti-biofilm activity of a chemically synthesized
paracentrin 1 (SP1) against a group of staphylococcal
reference strains and isolates and against P. aeruginosa
ATCC 15442.
Materials and methods
Synthetic peptide
The SP1 was purchased from CASLO, Lyngby, Denmark
utilizing the following sequence EVASFDKSKLK derived
from ESI-MS analysis. The peptide was synthesized using
Fmoc solid phase technology and the peptide content and
purity was determined by high performance liquid
chromatography (HPLC) and mass spectrometry (MS)
analysis.
Net molecular charge was calculated by using the following
formula (1) and the pI was calculated by using a web tool
(http://isoelectric.ovh.org/).
z ¼
X
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Ni
10pKai
10pH
−
X
j
Nj
10pH
10pH þ 10pKaj ð1Þ
Hydrophobic mean value was calculated by using the
Liu-Deber hydrophobicity scale (Liu and Deber 1998).
Secondary structure was evaluated utilizing the algorithm
of Wang et al. (2009), present in antimicrobial peptide
calculator web site (http://aps.unmc.edu/AP/prediction/
prediction_main.php). The helical wheel projection was
performed using the Gautier et al. (2008) algorithm
present in the HeliQuest site (http://heliquest.ipmc.cnrs.fr)
with a window size of 11 residues.Microbial strains
The staphylococcal reference strains used were: Staphylo-
coccus aureus ATCC 29213, Staphylococcus aureus ATCC
25923, Staphylococcus aureus ATCC 6538, and Staphylo-
coccus epidermidis RP62A, known for its ability to form a
biofilm (Schumacher-Perdreau et al. 1994). Four staphylo-
coccal isolates from the Istituto Zooprofilattico Sperimentale,
Sicily (IZS) bacterial collection including strain 657
isolated from a milk sample from an individual sheep
affected by mastitis, strain 688 and 700 and strain 702
isolated from bulk milk samples from different sheep
flocks. The isolates were selected on blood agar plates and
on Mannitol Salt Agar (Difco, Sparks, MD). The colonies
were typed by API Staph strip (bio-Mérieux) and tube
coagulase test was performed (Canicatti and Roch 1989).
Pseudomonas aeruginosa ATCC 15442, the reference
strain in official tests for antibacterial evaluation in vitro
(UNI EN European Standard), was also used in this study.Minimum inhibitory concentrations (MIC)
MICs were determined by a micro-method described
previously (Schillaci et al. 2005). Briefly, a series of solutions
of SP1 was prepared with a range of concentrations from
25 to 0.07 mg/ml(obtained by two-fold serial dilution). The
serial dilutions were made in Tryptic Soy Broth (TSB)
(Merck) in a 96-wells plate; to each well was added 10 μl of
a bacterial suspension from a 24 h culture containing
~1 × 106 CFU/ml. The plate was incubated at 37°C for
24 h; after this time, the MICs were determined by a micro-
plate reader (ELX 800, Bio-Tek Instruments), and defined
as the lowest concentration of compound whose O.D., read
at 570 nm, was comparable with the negative control wells
(broth only, without inoculum).Evaluation of Biofilm formation
All the bacterial reference strains were tested for their
ability to form biofilms. Briefly, bacteria were grown in
Tryptic Soy Broth (TSB, Sigma) containing 2% glucose
overnight at 37°C in a shaking bath and then diluted 1:200
to a suspension with optical density (OD) of about 0.040
at 570 nm corresponding to ~106 CFU/ml. Polystyrene
24-well tissue culture plates were filled with 1 ml of
diluted suspension and incubated for 24-hours at 37°C.
Then, the wells were washed three times with 1 ml of
sterile phosphate-buffered saline (PBS) and stained with
1 ml of safranin 0.1% v/v for 1 min. The excess stain was
removed by placing the plates under running tap water.
Plates were dried overnight in inverted position at 37°C.
Safranin stained adherent bacteria in each well were re-
dissolved to homogeneity in 1 ml of 30% v/v glacial acetic
acid, and the OD was read at 492 nm. Each assay was
performed in triplicate and repeated at least twice.
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Procedure described above was used to evaluate the activ-
ity of SP1 in preventing biofilm formation. Polystyrene
24-well tissue culture plates were filled with 1 ml of di-
luted bacterial suspension (OD of about 0.040 at 570 nm),
obtained and diluted as previously seen, and sub-MIC
concentrations, ranging from 6.2 to 0.7 mg/ml, of SP1
were directly added to the bacterial suspension at time
zero and incubated at 37°C for 24 hours. After that time
the wells were washed and stained with safranin as seen in
biofilm forming assay. By comparing the average optical
density of the growth in control wells with that in the
sample wells, the following formula was used to calculate
the percentages of inhibition for each concentration of the
sample:
Inhibition %ð Þ ¼ OD570 growth control−OD570 sample
OD570 growth control
 100
ð2Þ
Each assay was performed in triplicate and assays were
repeated at least twice.
Scanning electron microscopy
The effects of SP1 on formation of bacterial biofilm were
morphologically evaluated by scanning electron micros-
copy (SEM). Glass slides in the bottom of a polystyrene
24-well tissue culture plates, were filled with 1 ml of a
S. epidermidis RP62A suspension, obtained and diluted as
previously seen, and a sub-MIC concentration of 3.1 mg/ml
of SP1 was directly added at time zero and incubated at
37°C for 24 hours. After that time, the glass slides were
gently washed four times with PBS to remove non-
adherent bacteria and fixed with 2.5% glutaraldehyde-2%
paraformaldehyde in 0.1 M cacodilate buffer (pH 7.4) for
30 min at 4°C. The bacterial preparation were washed
with phosphate saline buffer PBS and post-fixed in
osmium tetroxide 1% for 30 min at 4°C, followed by an
ethanol dehydration series: 15 minutes in 50:50 ethanol:
H2O, 15 minutes in 75:25 ethanol: H2O, 15 minutes in
95:5 ethanol: H2O, and 30 minutes in 100% ethanol than a
critical point drying procedure was followed, and the
preparations were mounted on aluminium stubs, and gold
coated in a sputter coater. Imaging was conducted with a
LEO 420 scanning electron microscope as previously
reported (Arizza et al. 2011).
Haemolytic assay
The assay was performed as described (Arizza et al. 2013).
In brief, freshly collected rabbit erythrocytes (RE) with
heparin, kindly provided by the “Zooprophylaxis Institute
of Sicily” (Palermo, Italy), were washed (400 g for 10 min
at 4°C) to remove the buffy coat, and the erythrocytes ob-
tained were washed three times with phosphate-bufferedsaline (PBS: 6 mM KH2PO4; 30 mM Na2HPO4; 0.11 M
NaCl; pH 7.4) and suspended in 10 ml PBS to obtain an
80 × 106 cells/ml suspension. Aliquots of 200 μL of RE
suspension were mixed with 200 μl of SP1 concentrations
(1.5, 3.2, 6.2 and 50 mg/ml) prepared in PBS, two-fold se-
quentially diluted v/v with a PBS. After an 1 h incubation
at 37°C, the reaction mixture was centrifuged at 800 g for
15 min at 4°C to remove debris and residual erythrocytes.
The O.D. of haemoglobin release was measured spectro-
photometrically at a 541 nm wavelength. Spontaneous
haemoglobin release (0%) was estimated incubating the
RE with PBS while the complete haemolysis (100%) was
assessed incubating the erythrocytes in a solution of 0.1%
Triton-X 100 in distilled water and the haemolysis
percentage was calculated according to the following
equation:
Hemolysis %ð Þ ¼
OD541Hb release in the reaction mixture
−OD541spontaneous Hb release
OD541 complete Hb release
 100
ð3Þ
Molecular dynamics simulations
The molecular folding of the peptide in aqueous solution
was investigated in silico by molecular dynamics (MD)
simulations, following recently reported procedures
(Lauria et al. 2014; Lentini et al. 2014). In details, a 400 ns
of MD simulation was carried out at 300 K, in the explicit
water solvent and in the presence of 150 mM Na+ and Cl−
counterions, using the Amber99SB-ILDN force field
(Lindorff-Larsen et al. 2010) implemented in the GROMACS
4.6.5 software package (Pronk et al. 2013).
Results
Molecular Dynamics of SP1
SP1 is an 11-residue-long cationic peptide mainly
enriched by residues such as lysine, with a pI of 10.72 and
a net charge of +1 at pH 7.0.
To investigate SP1 in physiological conditions, we
performed a MD simulation using the model represented
in Figure 1. The in silico study provided a comprehensive
picture of the dynamic equilibrium existing among the
possible backbone conformations of the small oligopep-
tide. In fact, the root mean square deviations (RMSD) in
Figure 2 show that the peptide conformation continuously
and consistently changes during the 400 ns of simulation.
Essentially all possible backbone conformations are as-
sumed. However, interestingly, between 150 and 250 ns
the structure is more stable and preserved, before becom-
ing again flexible and random. To analyse this time region
quantitatively, we have reported the Ramachandran plot
in Figure 3 of snapshots sampled every 10 ns. This plot
shows that in this time range the different residues assume
Figure 1 Example of MD simulation box, showing the SP1
molecule, the solution counterions, Na+ (in blue) and Cl− (in cyan),
and the explicit water molecules (in red).
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3, 4 and 8 are in the beta sheet conformation, residues 5, 6
and 9 are in the left-handed helix conformation, residue 7
is in the alpha helix conformation, while residue 10 is in
the beta sheet conformation and only sporadically in the
alpha helix conformation. The corresponding structure is
depicted in Figure 4. The results obtained allow us to
confirm that polar and apolar residues are not segregated
on opposing surfaces through the long axis of the oligo-
peptide. In this peculiar conformation, the one that most
frequently occurs in the investigated simulation time, the
peptide possesses a hydrophobic non-amphipathic core
constituted by V2, A3, S4, F5 with a hydrophobic regionFigure 2 Plot of the RMSD obtained for SP1 up to 400 ns of MD simuplaced between E1 and D6. These features confer to SP1
properties similar to the AMPs with hydrophobic core.Antibacterial activity of SP1
SP1 was tested at concentrations ranging from 25 to
0.07 mg/ml against a group of Gram positive and Gram
negative reference strains. The antibacterial activity of SP1,
expressed as minimum inhibitory concentrations (MICs)
against planktonic cells of staphylococcal reference strains
and isolates from veterinary origin and P. aeruginosa is
listed in Table 1. All bacterial strains showed susceptibility
to the antibacterial action of SP1. In particular the strain of
S. epidermidis RP62A resulted to be the most susceptible,
indeed, the MIC value was 6.2 mg/ml, while others attested
to a value of 12.5 mg/ml. SP1 was active against all isolates
of animal origin strains and in particular showed the
highest activity against the strain #657 with a value of
6.2 mg/ml (Table 1).Interference with biofilm formation
The interference with biofilm formation of SP1 against
staphylococcal reference strains as S. aureus 25923, S.
aureus 29213, S. aureus 6538, S. epidermidis RP62A and
P. aeruginosa 15442 was observed. The inhibition was
very evident to the highest concentrations of SP1 at
6.2 mg/ml, when the values, for all strains, reached ap-
proximately 80%. At the lowest concentrations of SP1 the
degree of inhibition is reduced by following a dose de-
pendence. P. aeruginosa strain 15442 was the most sensi-
tive inhibitory activity of SP1, in fact, at a concentration of
3.1 mg/ml, a value of about 73% inhibition was observed,
while for the other strains the inhibition values were of
around 50% (Figure 5).lation.
Figure 3 Ramachandran plot showing the values of psi and phi angles assumed by residues 2–10 of SP1 between 150 and 250 ns of the
MD simulation.
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architecture of biofilm and the antibiofilm effects of SP1 on
bacterial biofilm of S. epidermidis RP62A (Figure 6). The
control biofilm after 24 h was composed by multilayered
conglomerated bacterial cells clusters that produced a
dense biofilm matrix (Figure 6A). Sub MIC concentration
(3.1 mg/ml) of SP1 was able to inhibit the formation of a
multistratified structure, in fact in the sample treated with
SP1 we found few monostratified bacterial cell clusters
respect to the growth control (Figure 6B).Figure 4 Molecular representation of SP1 at about 200 ns of MD show
surface is superimposed. Color code: acidic residues in red, basic residues iHaemolytic assay
The haemolytic activity of antimicrobial peptides against
mammalian erythrocytes is often used as a preliminary
evaluation of their selective toxicity and of the interactions
of the cationic peptides with negatively charged mem-
branes (Fischer et al. 2003; Wu et al. 2010) The performed
hemolytic experiment to evaluate the interaction and the
potential toxicity of the peptides SP1 did not show a
measurable toxic effect against RBC (~1%) at MIC
concentrations. A slight haemolytic activity, about 11.8%,ing the non amphipathic structure of the peptide. The potential
n blue, and hydrophobic residues in yellow.
Table 1 MIC values of SP1 tested against bacterial strains
Bacterial strains MIC (mg/ml)
S. aureus ATCC 25923 12.5
S. aureus ATCC 29213 12.5
S. aureus ATCC 6538 12.5
S. epidermidis RP62A 6.2
S. aureus 100 12.5
S. aureus 657 6.2
S. aureus 700 12.5
S. aureus 702 12.5
P. aeruginosa ATCC15442 12.5
MIC values for each strain are the means of three different assays performed
in duplicate
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(Figure 7).Discussion
The echinoderms are considered a good source for AMPs
and a variety of peptides with antimicrobial properties have
been isolated from them. Antimicrobial activity has been
reported in gonads of the asteroid Marthasterias glacialis
(Stabili and Pagliara 1994), and Paracentrotus lividus
contains, in the low molecular weight fraction (<5 kDa) of
acid precipitate of their coelomocytes, peptides with
antimicrobial activity against staphylococcal biofilms. In
addition, we recently reported that immune mediators cells
in the echinoderm Holothuria tubulosa is a source of novel
AMPs with anti-staphylococcal biofim activity (Schillaci
et al. 2013). Moreover, two cystein-rich AMPs, named
centrocyns, have been characterized in the green sea-urchin
Strongylocentrotus droebachiensis (Li et al. 2010).0
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Figure 5 Interference with biofilm formation of SP1 against reference sta
were evaluated comparing the samples with not-treated 24 h old biofilms and
29213, ( ) S. aureus 6538, ( ) S. epidermidis RP62A, ( ) P. aeruginosa 15442. DThe synthetic fragment SP1 of β-thymosin extracted
from coelomocytes of the P. lividus shares structural char-
acteristics of many antimicrobial peptides: it is a cationic
peptide and possesses a significant proportion (~40%) of
hydrophobic or non polar residues (Hancock and Lehrer
1998; Zasloff 2002). Although the α-helix is the most
common secondary structure for the antimicrobial activity
of AMPs (Mor and Nicolas 1994; Skerlavaj et al. 1996;
Storici et al. 1994; Tossi et al. 1994) the in silico study
suggests that the conformation assumed by SP1 (Figure 4)
might be responsible for the observed antimicrobial
activity. The helix structure of echinoderm AMPs shares a
characteristic amphipathic structure with alternating
hydrophobic and polar residues along the primary struc-
ture. According to the Shai-Matsuzaki-Huang model, the
peptides bind to the membrane surface first and then with
their amphipathic structure they enter into the membrane,
breaking up the lipid chains and forming transient pore;
this process can cause a collapse of the membrane at a
critical peptide concentration (Hancock and Chapple
1999; Huang 2000; Matsuzaki 1998; Shai 2002). The SP1
peptide has a structure very different from other echino-
derm AMPs (Schillaci et al. 2013; Schillaci et al. 2012).
Moreover, such structure, unexpectedly, does not have an
amphipathic nature with a hydrophobic face opposite to a
hydrophilic one, because the polar charged residues and
those hydrophobic are not arranged uniformly. The pep-
tide contains a sequence of four hydrophobic/non polar
residues which contribute to constitute a hydrophobic
core, flanked at both ends by cationic and polar residues
that can solubilize the peptides in aqueous solution
providing a binding site for bacterial membranes. This
particular conformation is different from other antimicro-
bial peptides, designed as transmembrane mimetic models
and that spontaneously become inserted into the cell1.5 0.7
ntration (mg/ml)
phylococcal and P. aeruginosa strains. The percentage of inhibition
staining with safranin. Bacterial strains ( ) S. aureus 25923, ( ) S. aureus
ata for each strain are the mean of three distinct experiments ± S.D.
Figure 6 SEM micrography showing the effect of sub-MIC concentration of SP1 on S. epidermidis RP62A biofilm formation. A) Growth
control (not treated with SP1); B) sample treated with a sub-MIC concentration (3.1 mg/ml) of SP1.
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et al. 2002).
We found that the SP1 showed a broad antimicrobial
activity against important pathogens such as S. aureus and
P. aeruginosa but it acts at high concentration (12.5 or
6.2 mg/ml) against planktonic forms of these two microor-
ganisms. Such weak activity is comparable to that reported
for a different Echinoderm, Holothuria tubulosa (Schillaci
et al. 2013) and to that of some described innate human
defence protein like lactoferrin in vitro (de Andrade et al.
2014). MD results suggest that the observed weak activity
could be due to the low stability of SP1, in fact, as showed
in RMSD plot (Figure 2), the molecule is stable only in a
limited time period and in this period it can present the
active conformation of Figure 1. However, SP1 shows an
interesting additional antimicrobial effect interfering with
biofilm formation in vitro of the above cited pathogens, at
lower concentrations than MIC evaluated against the
planktonic forms. The prevention of biofilm formation –
rather than its elimination – is the best strategy to contrast
the growth, as a sessile community, of many pathogens.0
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Figure 7 Hemolytic activity of SP1 peptides from Paracentrotus lividus h
1.5 mg/ml; 3.2 mg/ml; 6.2 mg/ml; 50 mg/ml. Data are the mean value of t
hemolysis ± SDWe do not know the antimicrobial mechanisms of SP1,
but we could speculate as for other cationic non-
amphipathic microbial peptides that the positive charges
carried by the peptide are essential for the membrane
binding through electrostatic interaction between residues
with anionic phospholipids. The peptide-membrane inter-
action could be responsible for membrane aggregation by
peptides bridging simultaneously two membranes or for
negative curvature of the membrane asymmetry that can
form tubes (Lamaziere et al. 2007). The synthetic SP1
could act like Dermaseptin S9, a non-amphipathic anti-
microbial peptides produced by the skin of the South
American hylid frog, Phyllomedusa sauvagei, that con-
tains, centrally located, a hydrophobic core that can insert
the peptide in interior membrane (Lequin et al. 2006).
Dermaseptin S9 exerts a microbicidal activity by pertur-
bating both the membrane interface and the hydrophobic
core of the bacterial membrane (Auvynet et al. 2008).
In a preliminary evaluation of selective toxicity, it was
gratifying to note the general lack of hemolysis of rabbit
erythrocytes by SP1, even at peptide concentrations up to6.2 50
trations (mg/ml)
emocytes against rabbit blood cells at different concentrations:
hree separate experiments and expressed as percentage of
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antimicrobial peptides for bacterial membranes may be
explicable, in part, by the differences in the compositions
of eukaryotic and prokaryotic membranes (Matsuzaki
1999; Zasloff 2002). The outer leaflet of mammalian cells
is predominantly composed of the zwitterionic phospho-
lipids phosphatidylcholine and sphingomyelin (Verkleij
et al. 1973), along with cholesterol (Turner and Rouser
1970), while bacterial membranes contain mainly anionic
phospholipids and no cholesterol (Brock 1974). In
addition, the outer surfaces of Gram-negative bacteria
contain lipopolysaccharides, while those of Gram-positive
bacteria contain teichoic acid, which in both cases add to
the negative charge of the bacterial surface (Brock 1974).
The cationic nature of native antimicrobial peptides
clearly contributes to their preferential recognition by the
negatively charged outer surfaces of bacterial membranes
(Oren and Shai 1998; Shai 1999).
The extensive clinical use of classical antibiotics has led
to the growing emergence of many medically relevant
resistant strains of pathogens (Patel 2005). Therefore, the
development of a new class of antimicrobials with a differ-
ent mechanism of action than conventional antibiotics has
become critical. The cationic antimicrobial peptides could
represent such a new class (Andreu and Rivas 1998;
Hancock 1997; Sitaram and Nagaraj 2002). The develop-
ment of resistance to membrane active peptides whose
sole target is the cytoplasmic membrane is not expected
because this would require substantial changes in the lipid
composition of cell membranes of microorganisms
(Hancock 2001).
The anti-adhesion property showed by SP1 against S.
aureus and P. aeruginosa strains is very interesting consid-
ering that the two opportunistic pathogens are able to
form biofilms in open wounds, such as chronic diabetic
foot ulcers, or infected wounds in clinical and veterinary
medicine. New antimicrobial agents that are effective
against staphylococci and P. aeruginosa to treat infected
wounds are needed, and a potential topical application of
SP1 could be supposed. Moreover, the two species are also
involved in food spoilage and biofilm formation of food
transmitted pathogens and an application of SP1 in the
food processing is possible and closer, at this stage of our
study, than application in clinical or veterinary health.
A chemotherapeutic approach combining conventional
antibiotics and novel anti-biofilm agents could be a new
strategy for the treatment of biofilm-associated infections
like mastitis in veterinary field or the topical treatment of
infected wounds in clinical and veterinary setting.
Finally, the tested synthetic peptide is a good starting point
to design new synthetic derivatives with modified chemical-
physical properties, with the aim to improve their antimicro-
bial activity against pathogens and their pharmaceutical
potential (Brogden and Brogden 2011; Huang et al. 2010).Competing interests
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